SynthesisLung2013
Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.
Synthesis in Lung, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma.Scientific reports · 2026Article
- Comparing Organs at Risk Sparing Between Intensity-Modulated Radiotherapy and Pencil-Beam Scanning Plans Based on Disease Location for Hodgkin and Non-Hodgkin Lymphoma.International journal of particle therapy · 2026Article
- Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.International journal of cancer · 2025Article
- Survivorship care for patients curatively treated for Hodgkin's and non-Hodgkin's lymphoma: a scoping review.Journal of cancer survivorship : research and practice · 2025Article
- Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.Pediatric radiology · 2024Article
- A case of concurrent follicular lymphoma and lung cancer requiring differentiation from lymph node metastasis.Thoracic cancer · 2024Article
- Screening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care.Systematic reviews · 2024Article
- Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening.Cancer medicine · 2024Article
- Cancer pain and alcohol self-medication.Journal of cancer survivorship : research and practice · 2023Article
- Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive-stage small cell lung cancer: A case report and literature review.Oncology letters · 2022Article
- Cancer Prevention for Survivors: Incidence of Second Primary Cancers and Sex Differences-A Population-Based Study from an Italian Cancer Registry.International journal of environmental research and public health · 2022Article
- The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study.Health expectations : an international journal of public participation in health care and health policy · 2022Article
- Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study).Translational lung cancer research · 2020Article
- Article
- Non-Small-Cell Lung Cancer After Mantle Radiation: A Case Report and Brief Review.Oncology (Williston Park, N.Y.) · 2019Review
- Conditional relative survival among long-term survivors of adolescent and young adult cancers.Cancer · 2018Article
- Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Article
- Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?Clinical lung cancer · 2017Article
- Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients treated for Hodgkin's lymphoma (HL) have a higher risk of developing second lung cancer (SLC) compared with the general population. The aim of this meta-analysis was to quantify such risk and to analyze contributing risk factors in HL survivors.
methodsAccording to predefined selection criteria, a literature search identified 21 studies that were included in the analysis.
resultsAfter eliminating overlapping or duplicate data, 793 (76 % males) incidences of SLC were encountered in 74,831 patients (58 % males) with HL over a median follow-up of 11.5 years. The median age at HL diagnosis and the median age at SLC diagnosis were 33.0 and 45.9, respectively. The mean latency between treatment of HL and development of SLC was 11.5 years. The pooled relative risk (RR) of SLC was 4.62 (95 % confidence interval [CI], 3.18-6.70], I (2) = 98 %), with a median absolute excess rate of 10.4 per 10,000 person-years. RR was positively related to study size, male-to-female ratio, institutional versus population-based data sets, and the use of any radiotherapy (RT) or combined modality therapy (CMT), while age at diagnosis of HL was not significant. The highest risk was shown among patients aged 15-24 years (RR = 8.76 [95 % CI, 4.55-16.89]), while the lowest risk occurred in patients ≥55 years at primary treatment (RR = 2.88 [95 % CI, 2.33-3.56]). RR increased by increasing duration of follow-up, reaching the highest value at 10-14 years (RR = 4.17 [95 % CI, 3.62-8.81]), but did not increase after ≥15 years (RR = 4.01 [95 % CI, 2.68-5.98]). RT only, CMT, or chemotherapy only was associated with RR (95 % CI) of 4.88 (3.14-7.60), 5.15 (4.08-6.50), and 2.39 (1.60-3.55), respectively. Patients with SLC demonstrated poor prognosis.
conclusionsThe current meta-analysis provided a detailed estimate of the risk of SLC among HL survivors. The obtained results may provide guidelines concerning lung cancer screening for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.